Award

Ask AI about this notice

Summarise, research or assess it with AI

View Markdown

Share this notice

Send this contract to a colleague

NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026

NHS England

This public procurement record has 7 releases in its history.

Award

10 Jul 2026 at 10:46

UK7 - Contract Details Notice
Award

09 Jun 2026 at 10:09

UK6 - Contract Award Notice
Tender

23 Feb 2026 at 14:41

UK4 - Tender Notice
PlanningUpdate

18 Feb 2026 at 12:08

UK2 - Preliminary Market Engagement Notice
Planning

14 Jan 2026 at 09:56

UK2 - Preliminary Market Engagement Notice
PlanningUpdate

03 Jun 2025 at 12:58

UK1 - Pipeline Notice
Planning

21 May 2025 at 13:15

UK1 - Pipeline Notice
Summary of the contracting process

NHS England has completed the procurement process for the supply of branded medicines under Tranche B, covering London and the South of England. The procurement was conducted as an open procedure, resulting in the awarding of contracts to multiple suppliers, including renowned pharmaceutical companies such as Pfizer, AbbVie, and GlaxoSmithKline. The framework agreement, set to commence on 1st September 2026, spans a two-year period with potential extensions up to 2030. The process, registered under the code NHS Branded Medicines - Tranche B, was conducted under the legal framework of the UK Public Contracts Regulations 2023.

This tender signifies a substantial opportunity for suppliers in the pharmaceutical industry, especially those with a focus on branded medicines. Given the scale and scope of the contracts awarded, both large corporations and SMEs were encouraged to participate, fostering competitive innovation across various therapeutic areas including interleukin inhibitors and cytokine modulators. The open competition format ensured a broad inclusion, allowing diverse businesses, regardless of size, to contribute to the NHS’s objective of delivering high-quality healthcare products. This framework presents a viable avenue for pharmaceutical companies aiming to expand their reach within the UK’s public health sector.

How relevant is this notice?

Notice Information

Notice Title

NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026

Notice Description

NHS Branded Medicines Tranche B - Lot 1 - London & South of England - CM/PHR/25/5731 Period of Framework Agreement: 1 September 2026 to 31 August 2028 with an option or option(s) to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Lot 2 - Ustekinumab for North of England and Midlands & East, period of Framework Agreement: 1st September 2026 to 31st August 2027 with an option or option(s) to extend for a further 12 months.

Lot Information

Lot 1 - Tranche B for London & South of England

NHS Branded Medicines - Tranche B for London & South of England

Options: With an option or option(s) to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

Renewal: With an option or option(s) to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

Lot 2 - Ustekinumab for North of England and Midlands & East

NHS Branded Medicines - Ustekinumab for North of England and Midlands & East

Options: With an option or option(s) to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.

Renewal: With an option or option(s) to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.

Planning Information

NHS England advises suppliers of an upcoming tender for the NHS Branded Medicines Agreement – Tranche B - Lot 1, scheduled to commence on 1 September 2026 for a 24-month term, with an option to extend for a further 24 months. Lot 2 - Ustekinumab for North of England and Midlands & East, period of Framework Agreement: 1st September 2026 to 31st August 2027 with an option or option(s) to extend for a further 12 months. The purpose of this notice is to inform existing and potential suppliers that, where deemed beneficial, a virtual 1:1 preliminary market meeting can be arranged. Please contact Trushal.Patel@nhs.net to register your interest. A seven-day window for queries will be available via Atamis after all sessions have concluded. This framework will cover six therapy areas including adalimumab, bevacizumab, cytokine modulators, interleukin inhibitors, JAK inhibitors, and monoclonal antibodies.

Notice Details

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-051a9d
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/065041-2026
Current Stage
Award
All Stages
Planning, Tender, Award

Procurement Classification

Notice Type
UK7 - Contract Details Notice
Procurement Type
Framework
Procurement Category
Goods
Procurement Method
Open
Procurement Method Details
Open procedure
Tender Suitability
SME
Awardee Scale
Large, SME

Common Procurement Vocabulary (CPV)

CPV Divisions

33 - Medical equipments, pharmaceuticals and personal care products

CPV Codes

33600000 - Pharmaceutical products

Notice Value(s)

Tender Value
£592,363,416 £100M-£1B
Lots Value
£592,363,417 £100M-£1B
Awards Value
£832,766,796 £100M-£1B
Contracts Value
£832,766,796 £100M-£1B

Notice Dates

Publication Date
10 Jul 20261 months ago
Submission Deadline
26 Mar 2026Expired
Future Notice Date
23 Feb 2026Expired
Award Date
1 Jun 20262 months ago
Contract Period
1 Sep 2026 - 31 Aug 2027 6-12 months
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Complete
Awards Status
Active, Pending
Contracts Status
Active

Buyer & Supplier

Contracting Authority (Buyer)

Main Buyer
NHS England
Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
LONDON
Postcode
SE1 8UG
Postcode Area
South East London
Country
England
Major Region (ITL 1)
TLI London
Basic Region (ITL 2)
TLI4 Inner London - East
Small Region (ITL 3)
TLI45 Lambeth
Delivery Location
TLC North East (England), TLD North West (England), TLF East Midlands (England), TLG West Midlands (England), TLI London, TLJ South East (England), TLK South West (England)
Local Authority
Lambeth
Electoral Ward
Waterloo & South Bank
Westminster Constituency
Vauxhall and Camberwell Green

Supplier Information

Number of Suppliers
27
Supplier Names

ABBVIE LTD

ACCORD-UK LTD

AMGEN LIMITED

AVENTIS PHARMA LIMITED

AVENTIS PHARMA LIMITED t-a Sanofi

Alfasigma UK Limited

BIOGEN IDEC LIMITED

Biosimilar Collaborations Ireland Limited

CELLTRION HEALTHCARE UK LIMITED

CELLTRION HEALTHCARE UNITED KINGDOM LIMITED

DR REDDY'S LABORATORIES (UK) LIMITED

FRESENIUS KABI LIMITED

GEDEON RICHTER (UK) LIMITED

GLAXOSMITHKLINE UK LIMITED

JANSSEN-CILAG LIMITED

MILPHARM LIMITED

ORGANON PHARMA (UK) LIMITED

ORIFARM UK LTD

PFIZER LIMITED

ROCHE PRODUCTS LIMITED

SAMSUNG BIOEPIS UK LIMITED

SANDOZ LIMITED

SWEDISH ORPHAN BIOVITRUM LTD

TEVA UK LIMITED

THORNTON & ROSS LIMITED

UCB PHARMA LIMITED

ZENTIVA PHARMA UK LIMITED

Further Information

Notice Documents

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

JSON Markdown

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

Loading OCDS record...